Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Myriad Genetics Inc (MYGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,139,810
  • Shares Outstanding, K 68,780
  • Annual Sales, $ 753,800 K
  • Annual Income, $ 125,300 K
  • 36-Month Beta 0.34
  • Price/Sales 1.51
  • Price/Book 1.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.22 +5.36%
on 12/01/16
18.03 -5.21%
on 11/14/16
+0.61 (+3.70%)
since 11/04/16
3-Month
15.92 +7.35%
on 11/03/16
22.40 -23.71%
on 09/15/16
-3.58 (-17.32%)
since 09/06/16
52-Week
15.92 +7.35%
on 11/03/16
44.57 -61.66%
on 12/08/15
-25.91 (-60.26%)
since 12/04/15

Most Recent Stories

More News
Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast...

Learn how to target a 20% return on Sears Holdings, or get option-trade ideas on Intrexon, Agios Pharmaceuticals, Mattel Inc. and Myriad Genetics or any stock you choose

InvestorsObserver issues critical PriceWatch Alerts for AGIO, MAT, MYGN, SHLD, and XON.

Crescendo Bioscience Announces Four Studies with Vectra(R) DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that four poster presentations on Vectra DA will be featured at the American College of Rheumatology...

Shares of MYGN Down 49.9% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 6 months, Myriad Genetics has returned 49.91% as of today's recent price of $17.38.

Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx(R)

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will submit its BRACAnalysis CDx test for approval by Japan's Pharmaceuticals and...

The GeneSight(R) Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder

Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight test will be presented at the Neuroscience Education Institute (NEI)...

Myriad Genetics Has Returned 54.0% Since SmarTrend Recommendation (MYGN)

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 6 months, Myriad Genetics has returned 54.01% as of today's recent price of $15.96.

Downgrade Alert for Myriad Genetics (MYGN)

Myriad Genetics (NASDAQ:MYGN) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $16.40 on volume of 7.1 million shares, above average daily volume of 853,000....

Myriad Genetics (MYGN) Earnings Miss, Revenues Top in Q1

Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 23 cents in the first quarter of fiscal 2017, missing the Zacks Consensus Estimate by 11.5%.

Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results

-- Total Revenues of $177.5 Million

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease....

See More

Support & Resistance

2nd Resistance Point 17.68
1st Resistance Point 17.42
Last Price 17.09
1st Support Level 16.78
2nd Support Level 16.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.